| Literature DB >> 28576136 |
Souvik Ghatak1, Payel Chakraborty1, Sandeep Roy Sarkar2, Biswajit Chowdhury2, Arup Bhaumik2, Nachimuthu Senthil Kumar3.
Abstract
BACKGROUND: The role of adenomatous polyposis coli (APC) gene in mitosis might be critical for regulation of genomic stability and chromosome segregation. APC gene mutations have been associated to have a role in colon cancer and since gastric and colon tumors share some common genetic lesions, it is relevant to investigate the role of APC tumor suppressor gene in gastric cancer.Entities:
Keywords: Adenomatous polyposis coli (APC); Cell cycle; Gastric adenocarcinomas; Immunoreactivity; Mutation
Mesh:
Substances:
Year: 2017 PMID: 28576136 PMCID: PMC5457612 DOI: 10.1186/s12881-017-0427-2
Source DB: PubMed Journal: BMC Med Genet ISSN: 1471-2350 Impact factor: 2.103
Somatic mutational profiling of APC gene exon 14 using PCR-RFLP
| Codon | Enzymes | Size of normal alleles (bp) | Mutation | Amino acids | Size of mutant alleles | Sample Frequency |
|---|---|---|---|---|---|---|
| 622b |
| 189,163 | TA | Y > a | 352 | 10% |
| 625b |
| 266, 86 |
| Q > a | 135, 131, 86 | 5% |
arepresents stop codon
brepresents Novel mutations (unreported in the database)
Clinicopathological features of gastric cancer patients (Stratified by age)
| Parameters | Younger age group (Age ≤ 45 years) | Older age group (Age 46–79 years) |
|
|---|---|---|---|
| Gender | |||
| Male | 06 (15%) | 16 (40%) | 0.326 |
| Female | 08 (20%) | 10 (25%) | |
| BMI (Mean ± SD) | 21.4 kg/m2 ± 3.6 | 22.1 kg/m2 ± 2.9 | 0.058 |
| Tumor size (cm), (mean ± SD) | 4.6 ± 2.8 | 4.9 ± 3.1 | 0.922 |
| Tumor location | |||
| Upper | 08 (20%) | 13 (32.5%) | 0.869 |
| Middle | 02 (5%) | 05 (12.5%) | |
| Lower | 04 (10%) | 06 (15%) | |
| Whole | 0 | 02 (5%) | |
| Type of gastrectomy | 0.186 | ||
| Total | 10 (25%) | 12 (30%) | |
| Subtotal | 04 (10%) | 14 (35%) | |
| Stage | |||
| Stage I | 0 | 0 | |
| Stage II | 7 (17.5%) | 12 (30%) | 0.828 |
| Stage III | 5 (12.5%) | 8 (20%) | |
| Stage IV | 2 (5%) | 6 (15%) | |
| Abdominal pain | 9 (22.5%) | 16 (40%) | 0.161 |
| Weight loss | 5 (12.5%) | 12 (30%) | 0.05 |
| Hemorrhage | 7 (17.5%) | 3 (7.5%) | 0.205 |
| Dysphagia | 6 (15%) | 5 (12.5%) | 0.76 |
| Early satiety | 3 (7.5%) | 3 (7.5%) | 1.00 |
| Vomiting | 4 (10%) | 12 (30%) | 0.045 |
| Increased Abdominal girth | 1 (2.5%) | 0 | 0.317 |
Values in parenthesis indicates percentage of that sample represented from the total number of studied samples
Immunohistochemical staining of APC protein in different gastric cancer stages
| Tissue Type | APC immunohistochemistry | |
|---|---|---|
| Positive | Negative | |
| Adjacent Normal cell | 40 (100%) | 0 |
| Tumor cell | ||
| Stage II | 19 (47.5%) | 0 |
| Stage III | 10 (25%) | 3 (7.5%) |
| Stage IV | 7 (17.5%) | 1 (2.5%) |
P value = 0.07
Values in parenthesis indicates percentage of that sample represented from the total number of samples
Fig. 1Microscopic view of well differentiated adenocarcinoma of gastric tumor cells. a Positive high immunoexpression of anti-APC antibody in cancer cell (b) Positive moderate immunoexpression of anti-APC antibody in cancer cell (c) Negative immunoexpression of anti APC antibody in cancer cell (d) Positive moderate immunoexpression of anti-APC antibody in adjacent normal cell (from negative immunoexpression cancer cell), represented by the brownish colour in the cytoplasm and membrane
Fig. 2Different Mutation in the exon 14 (g.127576C > A, g.127583C > T) of APC protein. a Wild type codon 622 (TAC) in adjacent normal sample, b Mutant type codon 622 (TAA) in tumor sample, c Wild type codon 625 (CAG) in adjacent normal sample, d Mutant type codon (TAG) in tumor sample
Fig. 3Circos plot of representative APC mutation in gastric tumor sample and their association with cancer stages, cell cycle, and APC protein expression. The frequency of occurrence of different factors such as mutations, APC protein expression pattern, ploidy level and tumor stages is depicted in the outer ring. The inner ring of circos plot depicts the association between the mutations, APC protein expression pattern, ploidy level and tumor stage involved in gastric cancer. Each factor has been assigned a color. The arc originates from mutations and APC protein expression status and terminates at tumor staging and ploidy level to compare the association between the origin and terminating factors. The area of each colored ribbon depicts the frequency of the samples related with the particular mutations and APC protein expression
Fig. 4Histogram of Cell cycle analysis of (a) adjacent control gastric cell and (b) Tumor gastric adenocarcinoma cell (p value = 0.071)
Detection of somatic mutations in APC gene exon 15
| Codon | Mutation | Amino acid change | Sift score | Polyphen2 score | SNPs & GO Effect/RI | Sample Frequency | Motifs | Domains | Amino acid property Change |
|---|---|---|---|---|---|---|---|---|---|
| 1058 | G | Asp(D) > Gly(G) | Pathological | 0.37 (Pathogenic) | Disease/3 | 5% | -- | Beta‐Catenin Binding | • The charge of the wild-type residue will be lost, this can cause loss of interactions with other molecules or residues |
| 1083 | GA | Asp(D) > Glu(E) | Natural | 0.08 (Benign) | Natural/1 | 5% | -- | -- | • The mutant residue is bigger, this might lead to bumps. |
| 1108 | A | Asn(N) > Ser(S) | Natural | 0.08 (Benign) | Disease/0 | 15% | -- | Beta‐Catenin Binding | • The mutation introduces a more hydrophobic residue at this position. This can result in loss of hydrogen bonds and/or disturb correct folding. |
| 1247 |
| Ala(A) > Thr(T) | Natural | 0.10 (Benign) | Natural/3 | 15% | GSK3 phosphorylation site | Beta‐Catenin Binding | • The hydrophobicity of the wild-type and mutant residue differs. |
| 1307 | A | Ile(I) > Lys(K) | Pathological | 0.72 (Pathogenic) | Disease/7 | 5% | WDR5 WD40 repeat (blade 5,6)‐binding ligand | Beta‐Catenin Binding | • The mutation introduces a charge, this can cause repulsion of ligands or other residues with the same charge. |
| 1317 |
| Glu(E) > Gln(Q) | Pathological | 0.41 (Pathogenic) | Disease/4 | 10% | Glycosaminoglycan attachment site | Beta‐Catenin Binding | • The charge of the wild-type residue will be lost, this can cause loss of interactions with other molecules or residues. |
a- represents Novel mutations (unreported in the database); RI - Reliability Index